Clinical Trials Browser

VGX-3100 × Clear all

NCT03603808 2025-07-16

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Phase 2 Completed

Squamous Intraepithelial Lesions, HIV Seropositivity

NCT03721978 2024-10-17

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Phase 3 Completed

203 enrolled 34 charts

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT03180684 2023-08-25

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Phase 2 Completed

33 enrolled 19 charts

Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

NCT03185013 2023-07-27

REVEAL 1

Phase 3 Completed

201 enrolled 23 charts

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT03499795 2023-07-14

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Phase 2 Completed

23 enrolled 19 charts

GastrointestinalGynecologic

Squamous Intraepithelial Lesions, Anus Neoplasms

NCT02163057 2021-01-22

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Phase 1/2 Completed

22 enrolled 14 charts

Head and Neck Squamous Cell Cancer

NCT01188850 2018-08-10

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Phase 1 Completed

Uterine Cervical Neoplasms

NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Phase 1 Completed

Uterine Cervical Neoplasms, Papillomavirus Infections